NovoCure (NVCR) Stock Overview
An oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
NVCR Community Fair Values
Create NarrativeSee what 26 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
NovoCure Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.93 |
| 52 Week High | US$20.06 |
| 52 Week Low | US$9.82 |
| Beta | 0.82 |
| 1 Month Change | 9.45% |
| 3 Month Change | -3.79% |
| 1 Year Change | -33.54% |
| 3 Year Change | -82.12% |
| 5 Year Change | -93.84% |
| Change since IPO | -34.74% |
Recent News & Updates
NVCR: Mixed Research Views And Trial Progress Will Shape Future Risk Balance
Analysts have trimmed their average price target for NovoCure by $1.00 to $13.50, citing updated assumptions for fair value, discount rate, revenue, profit margin and future P/E following recent mixed target revisions from the Street. Analyst Commentary Recent Street research presents a mixed picture for NovoCure, with one target cut and another raised in close succession.
NVCR: Recovering Procedure Trends And 2026 Tools Play Will Drive Upside
NovoCure Narrative Update The updated analyst price target for NovoCure reflects a modest upward move to $26.07. This is supported by mixed recent Street research, where some analysts highlight recovering end markets, healthier procedure and CapEx trends into 2026, and early recovery signs in China.
NVCR: Recovering Medtech Demand Will Support 2026 Tools Upside Potential
Narrative Update: NovoCure Price Target Reset Analysts have lifted their NovoCure price target by $5.38, citing updated assumptions that include a lower discount rate, higher modeled revenue growth and profit margin, and a slightly reduced future P/E multiple. Analyst Commentary Bullish analysts see the recent price target moves as part of a constructive re-rating story for NovoCure, with expectations focused on execution of growth initiatives and clearer earnings visibility over the medium term.Recent updates
NVCR: Mixed Research Views And Trial Progress Will Shape Future Risk Balance
Analysts have trimmed their average price target for NovoCure by $1.00 to $13.50, citing updated assumptions for fair value, discount rate, revenue, profit margin and future P/E following recent mixed target revisions from the Street. Analyst Commentary Recent Street research presents a mixed picture for NovoCure, with one target cut and another raised in close succession.NVCR: Recovering Procedure Trends And 2026 Tools Play Will Drive Upside
NovoCure Narrative Update The updated analyst price target for NovoCure reflects a modest upward move to $26.07. This is supported by mixed recent Street research, where some analysts highlight recovering end markets, healthier procedure and CapEx trends into 2026, and early recovery signs in China.NVCR: Recovering Medtech Demand Will Support 2026 Tools Upside Potential
Narrative Update: NovoCure Price Target Reset Analysts have lifted their NovoCure price target by $5.38, citing updated assumptions that include a lower discount rate, higher modeled revenue growth and profit margin, and a slightly reduced future P/E multiple. Analyst Commentary Bullish analysts see the recent price target moves as part of a constructive re-rating story for NovoCure, with expectations focused on execution of growth initiatives and clearer earnings visibility over the medium term.NVCR: Recovering Procedure Trends And 2026 Tools Setup Will Drive Upside
NovoCure’s updated analyst price target has moved modestly higher to about $26, as analysts factor in a slightly lower discount rate and different assumptions around long term growth, margins and future P/E multiples. Analyst Commentary Recent research on NovoCure highlights a mix of optimism around longer term growth optionality and caution around external policy risks and market rotations that could affect how quickly that potential is reflected in the share price.NVCR: Recovering Procedure Trends And 2026 Tools Setup Will Support Upside
Analysts have modestly lifted their fair value estimate for NovoCure to $25.21 from $24.07. This reflects updated views on revenue growth, profit margins, discount rates, and P/E assumptions following recent mixed price target changes on the Street.NovoCure: FDA Approval For PC Unlocked With TTFields Expansion Opportunity Approaching
Feb 12NovoCure Limited's (NASDAQ:NVCR) 26% Dip In Price Shows Sentiment Is Matching Revenues
Feb 12
NVCR: Recovering Procedure Trends And 2026 Tools Setup Will Support Shares
Narrative Update Analysts have trimmed their implied price target for NovoCure to roughly US$20 from US$22, citing survey work that points to recovering procedure and CapEx trends into 2026, early signs of improvement in China, and ongoing sector rotation alongside potential ACA and Medicare changes that they believe warrant closer attention. Analyst Commentary Recent research points to a mixed setup for NovoCure, with valuation expectations recalibrated but longer term growth and execution themes still in focus.NVCR: Recovering MedTech Demand And 2026 Setup Will Support Share Momentum
Analysts have nudged their fair value estimate for NovoCure slightly lower, trimming the target by under US$1 to reflect updated long-term assumptions and more conservative modeling, even as they factor in recovering end markets and 2026-focused sector views. Analyst Commentary Recent Street updates on NovoCure focus on slightly lower fair value targets and more conservative long-term models, even as some analysts highlight signs of healthier demand across medical technology and related capital spending into 2026.NVCR: Recovering Medtech Procedures And CapEx Trends Will Support Upside Potential
Analysts have trimmed their price targets on NovoCure to a US$20 to US$23 range, citing more conservative long term assumptions. They also point to recovering end markets, sector rotation and healthier MedTech procedure and CapEx trends into 2026 as key context for the updated outlook.NVCR: Long-Term Pipeline And Margin Outlook Will Support Upside Potential
Analysts have modestly raised their fair value estimate for NovoCure from $38.00 to about $41.25 per share, reflecting updated models that balance increased long term conservatism with slightly stronger profit margin expectations and a higher future earnings multiple. Analyst Commentary Analyst sentiment on NovoCure remains mixed, but recent updates show a constructive undertone even as some models become more conservative.NVCR: Future Clinical Data Will Support Share Price Momentum Despite Cautious Outlook
Analysts have modestly lowered their price target for NovoCure from $25.00 to $23.00, citing increased long-term caution in their updated assessments. Analyst Commentary Following the revised price target, analysts offered balanced perspectives on NovoCure's outlook, weighing both positive catalysts and ongoing challenges for the company.NVCR: Recent Clinical Progress Will Drive Upward Momentum Despite Raised Discount Rate
NovoCure Price Target Slightly Lowered Amid Updated Analyst Models Analysts have reduced their price target for NovoCure from $25.19 to $24.69 per share, citing more conservative long-term assumptions in their latest projections. Analyst Commentary Analyst perspectives on NovoCure's latest pricing and projections provide insight into key drivers and concerns affecting the company's valuation and outlook.NVCR: Regulatory Wins And Clinical Milestones Will Drive Oncology Expansion
Narrative Update: NovoCure Analyst Price Target Adjusted Analysts have modestly reduced their price target for NovoCure from $27.19 to $25.19. They cite increased long-term conservatism in their latest models.Investors Give NovoCure Limited (NASDAQ:NVCR) Shares A 27% Hiding
Aug 21NovoCure Limited's (NASDAQ:NVCR) P/S Still Appears To Be Reasonable
Jun 18Is NovoCure (NASDAQ:NVCR) Using Debt Sensibly?
May 22
New FDA Approvals And Clinical Trials Will Expand Future Cancer Treatment Options
Recent FDA approvals and successful trials position Novocure for growth as it expands into multiple oncology indications, boosting its eligible patient population and revenue potential.Some Confidence Is Lacking In NovoCure Limited (NASDAQ:NVCR) As Shares Slide 25%
Mar 01NovoCure's Expansion Strategy Struggles To Translate Approvals Into Growth
Feb 28Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?
Feb 12NovoCure Limited (NASDAQ:NVCR) Looks Just Right With A 84% Price Jump
Dec 03Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFields
Dec 02Analyst Estimates: Here's What Brokers Think Of NovoCure Limited (NASDAQ:NVCR) After Its Third-Quarter Report
Nov 01Is NovoCure (NASDAQ:NVCR) A Risky Investment?
Oct 17NovoCure: There Is Still More Upside
Oct 16NovoCure's Stock Stagnates Amid Lack Of Progress Beyond GBM
Oct 09Investors Appear Satisfied With NovoCure Limited's (NASDAQ:NVCR) Prospects
Sep 12NovoCure Limited: A Post Q2 Analysis
Jul 26NovoCure Limited Q1 Earnings: Core Business Accelerating
May 03NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?
Apr 08NovoCure: Sell The METIS-Inspired Rally
Mar 28Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio
Mar 03NovoCure: Stay Cautious Amid Positive Signs
Jan 19Shareholder Returns
| NVCR | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -5.2% | -5.3% | -0.2% |
| 1Y | -33.5% | -18.1% | 27.6% |
Return vs Industry: NVCR underperformed the US Medical Equipment industry which returned -15.3% over the past year.
Return vs Market: NVCR underperformed the US Market which returned 29.1% over the past year.
Price Volatility
| NVCR volatility | |
|---|---|
| NVCR Average Weekly Movement | 13.4% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: NVCR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NVCR's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,605 | Frank Leonard | www.novocure.com |
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
NovoCure Limited Fundamentals Summary
| NVCR fundamental statistics | |
|---|---|
| Market cap | US$1.38b |
| Earnings (TTM) | -US$136.23m |
| Revenue (TTM) | US$655.35m |
2.1x
P/S Ratio-10.1x
P/E RatioIs NVCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVCR income statement (TTM) | |
|---|---|
| Revenue | US$655.35m |
| Cost of Revenue | US$165.17m |
| Gross Profit | US$490.18m |
| Other Expenses | US$626.41m |
| Earnings | -US$136.23m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 30, 2026
| Earnings per share (EPS) | -1.18 |
| Gross Margin | 74.80% |
| Net Profit Margin | -20.79% |
| Debt/Equity Ratio | 57.3% |
How did NVCR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/30 10:22 |
| End of Day Share Price | 2026/04/29 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NovoCure Limited is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael King | Citizens JMP Securities, LLC |
| Gregory Gilbert | Deutsche Bank |
| Vijay Kumar | Evercore ISI |